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Abstract
Glycoprotein	NMB	(GPNMB)	is	highly	expressed	in	many	types	of	malignant	tumors	
and	thought	to	be	a	poor	prognostic	factor	in	those	cancers,	including	breast	cancer.	
Glycoprotein	NMB	is	a	type	IA	transmembrane	protein	that	has	a	long	extracellular	
domain	(ECD)	and	a	short	intracellular	domain	(ICD).	In	general,	the	ECD	of	a	protein	is	
involved	in	protein‐protein	or	protein‐carbohydrate	interactions,	whereas	the	ICD	is	
important	for	intracellular	signaling.	We	previously	reported	that	GPNMB	contributes	
to	the	initiation	and	malignant	progression	of	breast	cancer	through	the	hemi‐immu‐
noreceptor	tyrosine‐based	activation	motif	(hemITAM)	in	its	ICD.	Furthermore,	we	
showed	that	the	tyrosine	residue	in	hemITAM	is	involved	in	induction	of	the	stem‐like	
properties	of	breast	cancer	cells.	However,	the	contribution	of	the	ECD	to	its	tumori‐
genic	function	has	yet	to	be	fully	elucidated.	In	this	study,	we	focused	on	the	region,	
the	so‐called	kringle‐like	domain	(KLD),	that	is	conserved	among	species,	and	made	
a	 deletion	mutant,	GPNMB(ΔKLD).	 Enhanced	 expression	 of	WT	GPNMB	 induced	
sphere	 and	 tumor	 formation	 in	 breast	 epithelial	 cells;	 in	 contrast,	 GPNMB(ΔKLD)	
lacked	these	activities	without	affecting	its	molecular	properties,	such	as	subcellular	
localization,	Src‐induced	tyrosine	phosphorylation	at	least	in	overexpression	experi‐
ments,	and	homo‐oligomerization.	Additionally,	GPNMB(ΔKLD)	lost	its	cell	migration	
promoting	activity,	even	though	it	reduced	E‐cadherin	expression.	Although	the	in‐
teraction	partner	binding	to	KLD	has	not	yet	been	identified,	we	found	that	the	KLD	
of	GPNMB	plays	an	important	role	in	its	tumorigenic	potential.
K E Y W O R D S
epithelial‐mesenchymal	transition,	GPNMB,	kringle‐like	domain,	sphere	formation,	
tumorigenicity
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1  | INTRODUC TION
Glycoprotein	NMB	is	a	type	IA	transmembrane	protein	that	is	highly	
expressed	 in	many	types	of	cancers,	 including	melanoma,	glioblas‐
toma,	 and	breast	 cancer.	 It	 is	 considered	a	poor	prognostic	 factor	
in	those	cancers	and	it	might	be	an	attractive	therapeutic	target.1‐5
We	have	previously	reported	that	enhanced	expression	of	GPNMB	
induces	 EMT	 and	 increases	 sphere	 formation	 in	 vitro	 and	 tumor	
growth	in	vivo,	whereas	knockdown	of	GPNMB	attenuated	the	tumor‐
igenic	ability	of	breast	cancer	cells.6	We	also	showed	that	cell	surface	
expression	of	GPNMB	is	induced	in	limited	numbers	of	breast	cancer	
cells	in	sphere‐culture	conditions	in	vitro	and	in	growing	tumors	in	vivo	
and	induces	stem‐like	properties,	such	as	high	expression	of	stemness	
genes,	 low	 expression	 of	 proliferation	 genes,	 and	 high	 sphere	 and	
tumor	formation.7	These	functions	depend	on	the	tyrosine	residue	of	
the	hemITAM	in	the	ICD	of	GPNMB.6,7	In	addition,	Lin	et	al8	reported	
that	GPNMB	interacts	with	epidermal	growth	factor	receptor	and	that	
stimulation	 of	 heparin‐binding	 EGF	 triggers	 the	 phosphorylation	 of	
the	tyrosine	residue	in	hemITAM.	They	also	showed	the	significance	
of	tyrosine	phosphorylation	in	the	poorer	prognosis	of	breast	cancer	
patients.	These	findings	together	with	ours	suggest	that	both	the	ICD	
and	 the	ECD	are	essential	 for	 the	 tumorigenic	 function	of	GPNMB;	
however,	the	function	of	the	ECD	has	yet	to	be	fully	elucidated.
Glycoprotein	NMB	consists	of	a	long	ECD	that	contains	an	N‐ter‐
minal	signal	peptide,	an	RGD	motif,	a	PKD	domain,	and	a	KLD,	a	single‐
pass	transmembrane	domain,	and	a	short	ICD	that	harbors	a	hemITAM	
and	a	dileucine	motif.2,9‐11	The	RGD	motif	is	known	as	an	integrin‐bind‐
ing	sequence	and	has	been	shown	to	be	involved	in	the	migratory	ac‐
tivity	of	breast	cancer	cells12	and	cell‐cell	adhesion.13,14	Glycoprotein	
NMB	interacts	with	syndecan‐4,	which	is	expressed	on	the	surface	of	T	
cells,	through	the	PKD,	and	this	interaction	suppresses	T‐cell	activation	
and	proliferation.15‐19	So	far,	little	is	known	about	the	function	of	the	
KLD	in	GPNMB.	Therefore,	in	the	present	study,	we	clarified	the	contri‐
bution	of	the	KLD	to	the	tumorigenic	function	of	GPNMB.
2  | MATERIAL S AND METHODS
2.1 | Cells and cell culture
293T	cells	and	NMuMG	cells	were	obtained	 from	the	ATCC.	We	
cultured	these	cells	 in	DMEM	(Sigma‐Aldrich)	supplemented	with	
10%	FBS,	100	units/mL	penicillin	G,	and	0.1	mg/mL	of	streptomy‐
cin	sulfate	(Wako	Pure	Chemical	Industries).	NMuMG	cells	stably	
expressing	GPNMB,	 both	WT	 and	KLD‐deletion	mutant	 (ΔKLD),	
were	maintained	 in	 the	presence	of	puromycin	 (1	μg/mL;	Sigma‐
Aldrich).6	L	Wnt‐3A	cells	and	L	cells	(ATCC)	were	used	to	prepare	
Wnt3A	 conditioned	 medium	 and	 control	 medium	 as	 described	
previously.20
2.2 | DNA constructs and transfection
Glycoprotein	NMB	 and	 Src	 cDNA	were	 cloned	 previously,6 and 
GPNMB(ΔKLD)	 lacking	 amino	 acids	 420‐491	of	mouse	GPNMB	
was	 generated	 by	 PCR,	 followed	 by	 cloning	 into	 pCAGIP‐	 or	
pcDEF3‐expressing	 vectors.	 pCAG‐GS‐β‐catenin	 and	 TOP‐flash	
luciferase	reporter	were	described	previously.20	These	constructs	
were	transfected	 into	cells	by	use	of	PEI	Max	 (Polysciences).	To	
establish	 stably	 expressing	 cell	 lines,	NMuMG	cells	were	 trans‐
fected	 using	 Lipofectamine	 3000	 (Invitrogen)	 as	 described	
previously.6,21
2.3 | Immunoprecipitation
For	the	immunoprecipitation,	293T	cells	were	transfected	with	the	
indicated	plasmids,	and	the	cells	were	then	solubilized	in	lysis	buffer	
(20	mmol/L	Tris‐HCl,	pH	7.5,	150	mmol/L	NaCl,	1%	Nonidet	P‐40,	
2000	kIU/mL	aprotinin,	and	1	μg/mL	leupeptin).	The	debris	was	then	
precipitated	by	 centrifugation;	 a	 small	 amount	of	 total	 cell	 lysates	
was	collected	and	the	remainder	was	used	for	immunoprecipitation	
with	anti‐FLAG	Ab	(M2;	Sigma‐Aldrich).
2.4 | Sodium dodecyl sulfate‐PAGE and 
immunoblot analysis
The	 protein	 samples	 were	 subjected	 to	 SDS‐PAGE.	 The	 proteins	
were	 then	 electrotransferred	 to	 PVDF	 membranes	 (Millipore)	
and	 subjected	 to	 immunoblot	 analysis.	 Antibodies	 against	 FLAG	
(M2;	 Sigma‐Aldrich),	HA	 (3F10;	 Roche	Diagnostics),	 c‐Myc	 (9E10;	
Santa	 Cruz	 Biotechnology),	 and	 phosphorylated	 tyrosine	 (4G10;	
Millipore)	were	used.	The	reacted	Abs	were	detected	as	described	
previously.22
2.5 | Flow cytometry
293T	cells	were	transfected	with	the	indicated	plasmids	and	treated	
with	 trypsin	 (Sigma)	 to	 yield	 single	 cells.	 The	 floating	 single	 cells	
were	 incubated	 with	 anti‐GPNMB	 Ab	 (AF2550;	 R&D	 Systems),	
and	 then	with	Alexa	488‐labeled	donkey	anti‐goat	 IgG	 (Molecular	
Probes)	on	 ice	for	30	minutes.	The	samples	were	analyzed	using	a	
BD	FACSCalibur	 (BD	Biosciences)	and	BD	CellQuest	software	(BD	
Biosciences).
2.6 | Reverse transcription‐PCR and quantitative 
real‐time PCR
Reverse	 transcription‐PCR	 (RT‐PCR)	 was	 carried	 out	 as	 de‐
scribed	 previously.23	 In	 brief,	 total	 RNA	 was	 extracted	 using	
ISOGEN	 II	 reagent	 (Nippon	 Gene).	 Reverse	 transcription	 was	
undertaken	 using	 High	 Capacity	 RNA‐to‐cDNA	 Master	 Mix	
(Applied	 Biosystems)	 and	 semiquantitative	 RT‐PCR	 was	 car‐
ried	 out	 with	 the	 previously	 described	 specific	 primers6 and 
using	 Ex	 Taq	 polymerase	 (Takara).	 Real‐Time	 PCR	 was	 per‐
formed	using	GeneAce	 SYBR	quantitative	 real‐time	PCR	 (qPCR)	
mix	α	 Low	ROX	 (Nippon	Gene)	 and	 the	ABI7500	Fast	Sequence	
Detection	 system	 (Applied	Biosystems).	All	 samples	were	 run	 in	
triplicate	 in	 each	 experiment.	 Primer	 sequences	 are	 as	 follows:	
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mouse Axin2	 forward,	 5′‐TGACTCTCCTTCCAGATCCCA‐3′,	
and	 reverse	 5′‐TGCCCACACTAGGCTGACA‐3′);	 and	 mouse	 β‐
actin	 forward,	 5′‐CGATGCCCTGAGGCTCTTT‐3′,	 and	 reverse	
5′‐TGGATGCCACAGGATTCCA‐3′.
2.7 | Sphere formation
A	 total	 of	 5	 ×	 103	 NMuMG‐mock,	 NMuMG‐GPNMB(WT),	 or	
NMuMG‐GPNMB(ΔKLD)	 cells	 were	 cultured	 in	 DMEM/F12	
medium	 (Sigma‐Aldrich)	 supplemented	 with	 20	 μL/mL	 B27	
(Invitrogen),	 20	 ng/mL	 EGF	 (Sigma‐Aldrich),	 and	 20	 ng/mL	 basic	
fibroblast	growth	factor	(Wako	Pure	Chemical	Industries)	in	each	
ultra‐low	attachment	culture	dish	(35	mm;	Corning).	The	size	of	the	
spheres	was	measured	and	the	number	of	the	spheres	was	counted	
on day 7.
2.8 | Tumor formation
A	 total	 of	 1	 ×	 107	 NMuMG‐mock,	 NMuMG‐GPNMB(WT),	 or	
NMuMG‐GPNMB(ΔKLD)	 cells	 were	 injected	 s.c.	 into	 6‐week‐
old	 female	 ICR‐	nu/nu	mice	 (Clea	 Japan).	 The	mice	were	 killed,	
and	 the	 tumor	 grafts	 harvested	 at	 8	 weeks	 postinjection.	 The	
tumor	volumes	were	approximated	using	the	following	formula:	
volume	=	 0.5	 ×	a × b2,	 in	which	a and b	 are	 the	 lengths	 of	 the	
major	and	minor	axes,	respectively.	The	tumors	were	then	fixed	
in	phosphate‐buffered	formalin	solution	and	embedded	in	paraf‐
fin,	and	the	sections	were	subjected	to	H&E	staining	and	immu‐
nohistochemistry.	All	animal	experiments	were	carried	out	with	
approval	from	the	Animal	Ethics	Committee	of	the	University	of	
Tsukuba	 and	 in	 accordance	with	 the	 university's	 animal	 experi‐
ment	 guidelines	 and	 the	 provisions	 of	 the	 1995	Declaration	 of	
Helsinki.
2.9 | Transwell migration assay
A	 total	 of	 3	 ×	 104	 NMuMG‐mock,	 NMuMG‐GPNMB(WT),	 or	
NMuMG‐GPNMB(ΔKLD)	cells	were	seeded	into	a	Transwell	cham‐
ber	(8‐μm	pore;	Corning).	After	16	hours,	the	cells	were	fixed	with	
3.7%	formaldehyde	and	stained	with	0.5%	crystal	violet.	Four	high‐
power	 field	pictures	of	 the	 lower	 surface	of	each	Transwell	mem‐
brane	were	photographed	under	microscopic	observation,	and	the	
migrated	cell	numbers	were	counted.
2.10 | Immunofluorescence staining
The	cells	were	 fixed	 in	4%	paraformaldehyde.	After	 fixation,	we	
incubated	 the	 cells	 using	 PBS	 supplemented	with	 0.3%	 Triton‐X	
and	1%	BSA	for	cell‐membrane	permeabilization	and	blocking.	The	
primary	Abs	used	were	against	GPNMB	(AF2550;	R&D	Systems),	
LAMP1	 (Cell	 Signaling	 Technology),	 and	 EEA1	 (Cell	 Signaling	
Technology).	The	 reacted	Abs	were	detected	with	 fluorescence‐
conjugated	 anti‐rabbit	 IgG	 (Alexa	 Fluor	 568;	 Molecular	 Probes)	
and	 fluorescence‐conjugated	 anti‐goat	 IgG	 (Alexa	 Fluor	 488;	
Molecular	Probes).	TO‐PRO3	(Thermo	Fisher	Scientific)	was	used	
for	nuclear	staining.	For	the	actin	staining,	fluorescein	phalloidin	
(Molecular	 Probes)	 was	 used.	 A	 confocal	 laser‐scanning	 micro‐
scope,	the	TCS	SP8	(Leica	Microsystems),	was	used	for	the	detec‐
tion	and	image	taking.
2.11 | Immunohistochemical staining
The	 paraffin‐embedded	 tissue	 sections	 were	 deparaffinized	 in	
xylene,	 rehydrated	 in	 ethanol,	 and	 immersed	 in	 citrate‐NaOH	
buffer	 (10	mmol/L	sodium	citrate,	pH	6.0)	at	121°C	for	20	min‐
utes.	After	retrieval	of	antigenicity,	the	nonspecific	Ab	reaction	
was	blocked	in	blocking	solution	(PerkinElmer	Life	Sciences),	and	
the	 samples	were	 incubated	with	Abs	against	HA	 (3F10;	Roche	
Diagnostics),	 E‐cadherin	 (610181;	 BD	 Biosciences),	 and	 Ki‐67	
(Abcam).	After	 the	 sections	 had	been	washed,	 the	 reacted	Abs	
were	 detected	 using	 the	 Dako	 EnVision+	 System/HRP	 (DAB)	
(DakoCytomation).
2.12 | Transmission electron microscopy
Fresh	 tissues	 were	 fixed	 with	 2.5%	 glutaraldehyde	 in	 0.1	 mol/L	
phosphate	buffer	(LSI	Medience)	at	4°C,	and	after	the	samples	had	
been	washed	3	 times	with	0.1	mol/L	phosphate	buffer,	 they	were	
postfixed	in	1%	OsO4	for	1	hour	at	4°C.	After	being	dehydrated	in	
a	series	of	increasing	ethanol	concentrations,	the	samples	were	em‐
bedded	 in	Epon	815	 (Fujifilm).	The	ultrathin	sections	were	stained	
with	uranyl	acetate	and	lead	citrate	and	examined	under	a	transmis‐
sion	electron	microscope,	the	JEM‐1400	(JEOL).
2.13 | Sequence alignment
Protein	sequence	information	was	obtained	from	the	NCBI.	The	bio‐
informatic	software	Lasergene	(DNASTAR)	was	used	to	analyze	the	
homology	of	 the	 sequences.	 The	 alignment	 results	were	obtained	
using	the	MegAlign	program	with	the	Jotun	Hein	method.
2.14 | Luciferase reporter assay
Cells	 were	 transfected	 with	 the	 TOP‐flash	 firefly	 luciferase	 re‐
porter	and	pRL‐CMV	Renilla	luciferase	reporter.	Luciferase	activ‐
ity	 in	cell	 lysates	was	determined	by	a	Luciferase	reporter	assay	
system	 (Promega)	using	a	 luminometer	 (MicroLumat).	 Luciferase	
activities	 were	 normalized	 to	 corresponding	 Renilla	 luciferase	
activity.
2.15 | Statistical analysis
Quantitative	data	are	expressed	as	mean	±	SD.	The	statistical	analy‐
ses	were	undertaken	using	1‐way	ANOVA	with	the	Tukey	multiple	
comparison	 test	 with	 GraphPad	 Prism	 7	 software	 (GraphPad)	 or	
Student's	t	test	with	Excel	(Microsoft).	Probability	values	<0.05	were	
considered	significant.
2240  |     XIE Et al.
3  | RESULTS
3.1 | Glycoprotein NMB has a KLD that is conserved 
across species
To	 identify	the	 important	region	 in	the	ECD	of	GPNMB	in	terms	
of	 its	 tumorigenic	 potential,	 we	 reviewed	 its	 motif	 and	 domain	
structures	(Figure	1A).	Among	all	the	known	motifs	and	domains	
in	the	ECD,	little	is	known	about	the	function	of	the	KLD,	although	
the	KLD	of	PMEL,	a	GPNMB	homologous	protein,	promotes	amy‐
loid	 formation	by	facilitating	PMEL	oligomerization.24	 In	general,	
a	KD	contains	80	amino	acids	and	 its	 typical	 loop	structures	are	
formed	by	3	 intramolecular	disulfide	bonds.24	We	first	examined	
the	 conservation	 of	 the	KLD	 among	 species	 and	 found	 that	 the	
KLD	of	GPNMB	is	highly	conserved	across	species,	 including	the	
6	cysteines	that	are	important	 in	the	disulfide	bond	formation	in	
the	KD	(Figure	1B).
3.2 | Deletion of the KLD does not affect GPNMB 
subcellular localization, tyrosine phosphorylation, or 
homo‐oligomer formation
To	 investigate	 the	 function	 of	 the	 KLD	 in	 GPNMB,	 we	 con‐
structed	a	deletion	mutant	of	mouse	GPNMB,	GPNMB(ΔKLD)	in	
which	 amino	 acids	420‐491	are	deleted	 (Figure	2A).	After	 clon‐
ing	into	mammalian	expressing	vectors,	we	confirmed	its	expres‐
sion	in	293T	cells	(Figure	2B).	In	addition,	flow	cytometry	analysis	
revealed	that	both	GPNMB(WT)	and	GPNMB(ΔKLD)	proteins	were	
similarly	 expressed	 on	 the	 surface	 of	 293T	 cells	when	we	 tran‐
siently	overexpressed	them	(Figure	2C).	We	next	established	sta‐
bly	expressing	cell	lines	of	either	GPNMB(WT)	or	GPNMB(ΔKLD)	
using	NMuMG	cells:	NMuMG‐GPNMB(WT)	clone	3	and	clone	8	
(here	 called	 G3	 and	 G86)	 and	 NMuMG‐GPNMB(ΔKLD)	 clone	 7	
and	 clone	11	 (here	 called	ΔKLD7	and	ΔKLD11)	 (Figure	2D).	We	
next	undertook	immunofluorescence	staining	to	examine	the	sub‐
cellular	 localization.	 GPNMB(ΔKLD)	 colocalized	 mainly	 with	 an	
endosome	marker,	EEA1,	and	a	 lysosome	marker,	LAMP1,	as	did	
GPNMB(WT)	(Figure	2E),	indicating	that	deletion	of	KLD	does	not	
affect	its	subcellular	localization.	Next,	we	evaluated	the	tyrosine	
phosphorylation	by	Src	because	our	previous	study	showed	that	
GPNMB	was	phosphorylated	by	Src	on	the	tyrosine	residue	in	its	
hemITAM.6	 As	 shown	 in	 Figure	 2F,	 the	 deletion	 of	KLD	did	 not	
influence	the	phosphorylation	of	GPNMB,	at	least	by	coexpressed	
Src	in	293T	cells.	We	also	found	that	GPNMB	could	form	a	homo‐
oligomer.	Therefore,	we	investigated	whether	GPNMB(ΔKLD)	can	
also	 make	 a	 homo‐oligomer.	 Immunoprecipitation‐immunoblot	
analysis	showed	that	KLD	is	not	responsible	for	the	oligomer	for‐
mation	(Figure	2G).	Although	deletion	of	the	whole	domain	some‐
times	results	in	a	nonfunctional	protein,	these	results	suggest	that	
the	deletion	of	 the	KLD	does	not	 affect	 the	basic	 properties	of	
GPNMB,	 such	 as	 subcellular	 localization,	 tyrosine	 phosphoryla‐
tion,	 and	homo‐oligomer	 formation.	Therefore,	we	continued	 to	
investigate	the	tumorigenic	functions	of	GPNMB(ΔKLD).
F I G U R E  1  Kringle‐like	domain	
(KLD)	of	glycoprotein	NMB	(GPNMB)	is	
conserved	among	species.	A,	2D	scheme	
of	human	and	mouse	GPNMB	showing	the	
extracellular	domain	consisting	of	a	signal	
peptide	(SP),	an	arginyl‐glycyl‐aspartic	
acid	motif	(RGD),	a	polycystic	kidney	
disease	domain	(PKD),	and	a	KLD,	the	
single‐pass	transmembrane	domain	(TM),	
and	the	intracellular	domain	consisting	
of	a	hemi‐immunoreceptor	tyrosine‐
based	activation	motif	(hemITAM)	and	a	
dileucine	motif.	B,	Conservation	of	the	
KLD	among	species.	Asterisks	indicate	the	
conserved	cysteines	in	the	domain
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3.3 | Kringle‐like domain is important in GPNMB‐
induced tumorigenic potential
To	 investigate	 the	 importance	 of	 the	 KLD	 in	 GPNMB‐induced	 tumo‐
rigenic	growth,	we	undertook	assays	of	in	vitro	sphere	formation	and	in	
vivo	 tumor	 formation.	 GPNMB(ΔKLD)‐expressing	 cells	 showed	 signifi‐
cantly	lower	sphere‐forming	activity	than	that	of	GPNMB(WT)‐expressing	
cells	 (Figure	3A,	Table	 S1).	When	we	 injected	 cells	 of	 either	NMuMG‐
GPNMB(WT)	or	NMuMG‐GPNMB(ΔKLD)	s.c.	into	nude	mice,	the	tumors	
from	the	GPNMB(ΔKLD)‐expressing	cells	were	significantly	smaller	and	
had	a	lower	incidence	than	those	from	the	GPNMB(WT)	cells	(Figure	3B,C,	
Table	S2).	These	results	indicate	the	essential	contribution	of	the	KLD	to	
GPNMB‐induced	tumorigenic	growth	in	both	in	vitro	and	in	vivo	systems.
3.4 | Deletion of the KLD partially maintains cellular 
junctions and polarity
We	 next	 analyzed	 each	 tumor	 histologically.	 On	 H&E	 staining,	 tu‐
bular	 structures	 were	 observed	 in	 the	 tissue	 of	 the	 NMuMG‐mock	
cells,	 suggesting	 their	 epithelial	 feature.	 In	 contrast,	 the	 tumor	 of	
NMuMG‐GPNMB(WT)	cells	consisted	of	mesenchyme‐like	cells	and	no	
tubule‐like	structures	were	seen,	as	we	already	reported.6	To	our	surprise,	
the	NMuMG‐GPNMB(ΔKLD)	cells	formed	tubular	structures,	indicating	
that	these	cells	keep	their	cell‐cell	junction	and	cellular	polarity	forma‐
tion	(Figure	4A).	Additionally,	we	undertook	immunohistochemical	stain‐
ing	using	anti‐HA	Ab	to	detect	the	expression	of	either	GPNMB(WT)	or	
GPNMB(ΔKLD)	in	the	tumors.	As	shown	in	Figure	4B,	most	of	the	tumor	
cells	in	the	grafts	were	HA‐positive	in	both	cases.	These	results	indicated	
that	 the	mesenchyme‐like	 tumor	 cells	 in	 the	GPNMB(WT)	 tumor	and	
cells	making	tubular	structures	in	the	GPNMB(ΔKLD)	tumor	were	derived	
from	NMuMG	cells	that	express	either	GPNMB(WT)	or	GPNMB(ΔKLD).	
Interestingly,	we	observed	the	expression	of	E‐cadherin	in	the	cell‐cell	
border	of	the	tubule‐like	structures	in	the	mock	graft,	whereas,	like	the	
GPNMB(WT)‐expressing	 cells,	 the	 GPNMB(ΔKLD)‐expressing	 cells	
lost	 E‐cadherin	 expression	 even	 if	 tubular	 structures	were	 generated	
(Figure	4C).	Furthermore,	the	GPNMB(ΔKLD)	tumor	had	fewer	Ki‐67‐
positive	cells	 (a	proliferation	marker)	 than	did	the	GPNMB(WT)	tumor	
(Figure	4D),	resulting	in	slower	growth	of	the	grafts	in	vivo.
To	examine	the	cellular	junction	formation,	we	used	transmission	
electron	microscopy	observation	to	compare	the	GPNMB(WT)	and	
F I G U R E  2  Deletion	of	the	kringle‐like	domain	(KLD)	from	glycoprotein	NMB	(GPNMB)	does	not	affect	its	basic	properties.	A,	2D	scheme	
of	mouse	WT	GPNMB,	and	a	KLD	deletion	mutant	(ΔKLD).	TM,	transmembrane	domain.	B,	Exogenous	expression	of	GPNMB(WT)	and	
GPNMB(ΔKLD)	in	293T	cells.	293T	cells	were	transfected	with	pCAGIP‐GPNMB(WT)‐FLAG/HA	or	pCAGIP‐GPNMB(ΔKLD)‐FLAG/HA,	
and	immunoblot	analysis	for	FLAG	was	carried	out	to	detect	GPNMB(WT)	and	GPNMB(ΔKLD).	C,	Detection	of	cell‐surface	expression	
of	GPNMB(WT)	and	GPNMB(ΔKLD)	in	293T	cells	by	flow	cytometry.	Black	line,	empty	vector	control;	red	line,	GPNMB(WT);	blue	line,	
GPNMB(ΔKLD).	D,	Stably	expressing	cell	lines	were	established	as	NMuMG‐mock	cells	(Mock),	NMuMG‐GPNMB(WT)‐FLAG/HA	cells	
(clone	3	[G3]	and	clone	8	[G8]),	and	NMuMG‐GPNMB(ΔKLD)‐FLAG/HA	cells	(clone	7	[∆K7]	and	clone	11	[∆K11]).	Detection	of	exogenous	
GPNMB	protein	expression	was	undertaken	by	immunoblot	analysis	for	HA.	β‐actin	was	used	as	the	loading	control.	E,	Immunofluorescence	
staining	showing	the	subcellular	localization	of	GPNMB(WT)	or	GPNMB(ΔKLD)	(green)	in	G8	and	∆K11	cells.	Early	endosome	antigen	
1	(EEA1;	red)	is	an	endosomal	marker	and	lysosome‐associated	membrane	protein	1	(LAMP1;	red)	is	a	lysosomal	marker.	Scale	bar,	
20 μm.	F,G,	Tyrosine	phosphorylation	and	oligomer	formation	of	GPNMB.	293T	cells	were	transfected	with	the	indicated	plasmids,	and	
immunoprecipitation	(IP)	was	carried	out	using	anti‐FLAG	Ab,	followed	by	immunoblot	(IB)	analysis	with	anti‐phosphorylated	tyrosine	
(4G10),	anti‐FLAG,	and	anti‐Myc	Abs	to	detect	Src‐induced	tyrosine	phosphorylation	of	GPNMB	(F),	and	with	anti‐His	and	anti‐FLAG	Abs	to	
detect	oligomer	formation	of	GPNMB	(G)
F I G U R E  3  Deletion	of	the	kringle‐like	domain	(KLD)	attenuates	the	tumorigenic	ability	of	glycoprotein	NMB	(GPNMB).	A,	Sphere‐
forming	abilities	of	NMuMG‐mock,	NMuMG‐GPNMB(WT)	(G3	and	G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	and	∆K11)	cells	were	
examined.	Only	spheres	larger	than	50	μm	in	diameter	were	counted.	Data	are	presented	as	mean	±	SD;	n = 3	replicates,	representative	of	3	
independent	experiments.	**P < 0.01,	****P < 0.0001	(vs	mock),	#P < 0.05,	####P < 0.0001	(vs	G3	and	G8),	1‐way	ANOVA	with	Tukey	multiple	
comparison	test.	B,C,	Tumor	growth	abilities	of	NMuMG‐mock,	NMuMG‐GPNMB(WT)	(G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	and	∆K11)	
cells	examined	by	s.c.	injection	into	ICR‐nu/nu	mice.	Macroscopic	view	(B)	and	measured	volumes	(C).	Data	are	presented	as	mean	±	SD;	n = 5	
mice.	****P < 0.0001	(vs	mock),	####P < 0.0001	(vs	G8),	1‐way	ANOVA	with	Tukey	multiple	comparison	test
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GPNMB(ΔKLD)	 grafts	with	 the	mock	 grafts.	 Tight	 junctions	were	
observed	 in	 the	mock	 grafts,	whereas	 none	 could	 be	 observed	 in	
the	GPNMB(WT)	 grafts;	 in	 addition,	 no	 villi	 could	 be	 observed	 in	
the	 GPNMB(WT)	 grafts,	 indicating	 loss	 of	 the	 epithelial	 feature.	
However,	the	GPNMB(ΔKLD)	tumors	seemed	to	have	tight	junction‐
like	adhesion	structures,	whereas	the	GPNMB(WT)	tumors	did	not	
(Figure	4E).	In	other	words,	GPNMB(ΔKLD)	had	less	disruption	of	cell	
polarity,	despite	not	having	E‐cadherin	and	mature	tight	junctions.
3.5 | Deletion of the KLD maintains the GPNMB 
function to suppress E‐cadherin expression but 
impairs its function to activate cellular migration and 
Wnt/β‐catenin signaling
We	 further	 examined	 the	 phenotypes	 of	 GPNMB(ΔKLD)	 cells	 in	
terms	of	the	induction	of	EMT.	Previously,	we	reported	that	enhanced	
expression	 of	 GPNMB(WT)	 induces	 EMT	 phenotypes	 in	 NMuMG	
cells,	such	as	downregulation	of	E‐cadherin,	promotion	of	cellular	mi‐
gration	and	 invasion,	and	 induction	of	stem‐like	properties	 in	breast	
cancer cells.6,7	As	shown	in	Figure	5A	and	5B,	GPNMB(ΔKLD)	induced	
suppression	of	E‐cadherin,	 as	did	GPNMB(WT).	However,	when	we	
investigated	the	actin	fiber	structures,	GPNMB(WT)	activated	stress	
fiber	 formation,	whereas	 GPNMB(ΔKLD)	 retained	 the	 cortical	 actin	
fibers	 (Figure	 5C).	 Furthermore,	 a	 Transwell	 migration	 assay	 indi‐
cated	that	GPNMB(ΔKLD)	lacked	the	cell	migration‐promoting	effect	
(Figure	5D,	Table	S3).	Taken	together,	these	findings	indicate	that	the	
deletion	of	the	KLD	from	GPNMB	could	impair	GPNMB‐induced	mo‐
tility	even	if	suppression	of	E‐cadherin	was	observed	by	stable	expres‐
sion	of	GPNMB(ΔKLD)	 in	NMuMG	cells.	The	molecular	mechanism	
that	explains	how	deletion	of	the	KLD	partially	impairs	EMT	and	the	
cell	migration‐inducing	 activity	of	GPNMB	has	not	been	 fully	 eluci‐
dated	yet,	but	our	preliminary	examination	indicated	the	impairment	
F I G U R E  4  Deletion	of	the	kringle‐
like	domain	partially	maintains	cellular	
junctions	and	polarity.	A‐D,	Histology	of	
the	xenograft	tumors	shown	in	Figure	
3C	was	determined	by	H&E	staining	(A)	
and	immunohistochemical	staining	for	
HA	(B),	E‐cadherin	(C),	and	Ki‐67	(D).	
Scale	bar,	50	μm.	E,	Transmission	electron	
microscopic	images	of	the	xenografts	of	
NMuMG‐mock,	NMuMG‐GPNMB(WT)	
(G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	
and	∆K11)	cells	as	indicated.	Arrow,	
microvilli;	black	arrowhead,	tight	junction	
structure;	red	arrowhead,	tight	junction‐
like	structure
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of	Wnt/β‐catenin	signaling	detected	by	TOP‐flash	reporter	assay	and	
Axin2	mRNA	levels	(Figure	5E,F).	Therefore,	supportive	effects	on	Wnt	
signaling	are	a	possible	molecular	function	of	GPNMB	KLD.
4  | DISCUSSION
This	is	the	first	report	to	identify	the	importance	of	the	region	of	amino	
acids	420‐491	in	the	ECD	of	mouse	GPNMB,	a	region	called	the	KLD,	for	
the	tumorigenic	function	of	GPNMB,	such	as	sphere	formation	in	vivo	and	
tumor	growth	in	vivo	(Figure	3).	NMuMG‐GPNMB(ΔKLD)	cells	formed	
tubular	structures	in	the	tumor	even	though	the	cells	did	not	express	E‐
cadherin,	which	is	involved	in	the	adherence	junction.	Tight	junction‐like	
structures	were	formed	in	the	tumor	of	NMuMG‐GPNMB(ΔKLD),	which	
was	 not	 observed	 in	 the	 NMuMG‐GPNMB(WT)	 tumor	 (Figure	 4A,B).	
Tight	 junctions	are	associated	with	maintenance	of	cell	polarity;	there‐
fore,	 these	 results	might	 explain	why	GPNMB(ΔKLD)‐expressing	 cells	
partially	retain	cell	polarity	when	compared	with	GPNMB(WT).
We	 previously	 reported	 that	 expression	 of	 GPNMB(WT)	 fully	
induces	EMT	in	NMuMG	cells.6	In	the	current	study,	we	have	con‐
firmed	 that	 overexpression	 of	 GPNMB(ΔKLD)	 suppressed	 E‐cad‐
herin	expression	at	both	the	mRNA	and	the	protein	 levels,	as	well	
as	GPNMB(WT)	did	 (Figure	5A,B).	 In	contrast,	GPNMB(ΔKLD)	did	
not	 induce	 stress	 fiber	 formation	nor	 cell	migration	 (Figure	5C,D).	
Epithelial‐mesenchymal	transition	is	a	biological	process	that	allows	
epithelial	 cells	 to	 harbor	 mesenchymal	 phenotypes,	 which	 acti‐
vates	cell	migration,	 invasiveness,	and	resistance	to	apoptosis,	and	
also	 contributes	 to	 induction	 of	 stem‐like	 properties.25‐27	 During	
EMT,	dissolution	of	 adherence	 junction	proteins	 and	disruption	of	
the	tight	junctions	lead	the	cells	to	lose	their	cell‐cell	adhesion	and	
apical‐basal	polarity,	and	thus,	they	become	migratory	and	invasive.	
However,	 sometimes	 it	 is	not	easy	 to	divide	cancer	cells	 into	cells	
with	 only	 epithelial	 or	mesenchymal	 features,	 and	 cells	with	 both	
epithelial	 and	 mesenchymal	 phenotypes	 have	 recently	 been	 re‐
ported,	which	is	termed	partial	EMT.28,29	Although	the	phenotypes	
of	 NMuMG‐GPNMB(ΔKLD)	 are	 different	 from	 those	 of	 complete	
F I G U R E  5  Deletion	of	the	kringle‐like	domain	(KLD)	maintains	the	glycoprotein	NMB	(GPNMB)	function	to	suppress	E‐cadherin	
expression	but	impairs	its	function	to	activate	cellular	migration	and	Wnt/β‐catenin	signaling.	A,B,	Expressions	of	GPNMB,	E‐cadherin,	
and β‐actin	in	NMuMG‐mock,	NMuMG‐GPNMB(WT)	(G3	and	G8),	and	GPNMB(ΔKLD)	(∆K7	and	∆K11)	cells	were	examined	by	RT‐PCR	for	
mRNA	(A)	and	by	immunoblot	analysis	for	proteins	(B).	C,	Immunofluorescence	staining	showing	stress	fiber	formation	in	NMuMG‐mock,	
NMuMG‐GPNMB(WT)	(G3	and	G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	and	∆K11)	cells.	Actin	(green)	was	stained	using	phalloidin	(green),	
and	TO‐PRO3	(magenta)	was	used	to	indicate	the	nuclei.	Scale	bar,	20	μm.	D,	Migration	of	NMuMG‐mock	and	NMuMG‐GPNMB(WT)	(G3	
and	G8),	and	NMuMG‐GPNMB(ΔKLD)	(∆K7	and	∆K11)	cells	was	examined	by	Transwell	migration	assay.	Data	are	presented	as	mean	±	SD;	
n = 3	replicates,	representative	of	3	independent	experiments.	****P < 0.0001	(vs	mock),	####P < 0.0001	(vs	G3	and	G8),	1‐way	ANOVA	
with	Tukey	multiple	comparison	test.	Scale	bar,	200	μm.	E,F,	Effects	of	GPNMB(WT)	and	GPNMB(DKLD)	on	Wnt/β‐catenin	signaling.	
NMuMG‐mock	and	NMuMG‐GPNMB(WT)	G8	and	NMuMG	‐GPNMB(ΔKLD)	ΔK7	cells	were	transfected	with	TOP‐flash	firefly	luciferase	
reporter	and	pRL‐CMV	Renilla	luciferase	reporter	with/without	pCAG‐GS‐β‐catenin	expressing	vectors.	Data	are	presented	as	mean	±	SD;	
n	=	3.	**P < 0.01,	Student's	t	test.	ns,	not	significant	(E).	NMuMG‐mock	and	NMuMG‐GPNMB(WT)	G8	and	NMuMG‐GPNMB(ΔKLD)	ΔK7	
cells	were	treated	with	Wnt3A	conditioned	medium	or	control	medium	for	3	h	and	Axin‐2	mRNA	was	measured	by	quantitative	PCR	and	
normalized	to	β‐actin	expression	levels.	Data	are	presented	as	mean	±	SD;	n	=	3.	***P < 0.001,	Student's	t	test	(F)
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EMT	and	partial	EMT,	it	might	be	a	kind	of	intermediate	phenotype	
between	epithelial	 and	mesenchymal,	 resulting	 in	 fewer	migratory	
and	tumorigenic	abilities.
The	point	mutant	in	which	the	tyrosine	residue	in	hemITAM	was	
altered	 to	 phenylalanine,	GPNMB(YF),	 totally	 lost	 EMT	 and	 stem‐
like	 properties	 inducing	 activity.6,7	 GPNMB(YF)	 did	 not	 suppress	
E‐cadherin	 and	 lacked	 the	 promoting	 effect	 on	 cellular	 migration	
and	sphere	and	tumor	formation,6	indicating	the	crucial	role	of	the	
tyrosine	 residue	 in	 the	 tumorigenic	 ability	 of	 GPNMB.	 However,	
deletion	 of	 the	 KLD	 impaired	 the	 tumorigenic	 potential,	 although	
GPNMB(ΔKLD)	could	be	phosphorylated	by	Src	when	we	transiently	
overexpressed	both	of	them	(Figure	2F).	Phosphorylation	of	endog‐
enous	GPNMB	hemITAM	tyrosine	 in	sphere	or	 in	tumor	could	not	
be	 directly	 detected;	 however,	 our	 previous	 and	 current	 findings	
suggest	that	this	tyrosine	phosphorylation	is	crucial,	and	additional	
mechanisms	through	KLD	could	be	working	to	fully	trigger	the	tum‐
origenic	function	of	GPNMB.
The	KD	is	composed	of	80	amino	acids	and	3	intramolecular	di‐
sulfide	bonds	to	make	a	typical	loop	structure.	It	is	thought	to	be	in‐
volved	in	the	interactions	of	proteins,	lipids,	and	small	molecules.30	It	
is	found	in	proteins	such	as	coagulation	factors	(prothrombin	and	co‐
agulation	factor	XII),31	proteases	(urokinase,	plasminogen,	plasmin‐
ogen	activator,	and	serine	proteases),31	growth	factors	(hepatocyte	
growth	factor),32	and	receptors	 (RORs	and	MuSK).33,34	Both	RORs	
and	MuSK	contain	KD	and	cysteine	rich	domain,	which	 is	 thought	
to	be	 responsible	 for	Wnt	 ligand	binding,	 in	 their	ECD.	Wnt5A	 in‐
duces	 ROR1	 and	 ROR2	 heterodimerization	 through	 KD,	 and	 acti‐
vates	chemotaxis	and	proliferation	of	leukemia	cells.35	Additionally,	
MuSK	is	also	involved	in	the	noncanonical	Wnt	signaling	pathway.36 
Recent	 publications,	 however,	 showed	 that	GPNMB	 is	 involved	 in	
Wnt/β‐catenin	signaling	in	glioma,	cervical	cancer,	and	breast	cancer	
models.37‐39	These	findings	bring	us	one	possibility	that	the	KLD	of	
GPNMB	is	somehow	involved	in	the	Wnt	signaling	pathway	and	our	
initial	 experiments	 suggested	 that	GPNMB	KLD	might	 have	 some	
function	 to	support	Wnt/β‐catenin	signaling	 (Figure	5E,F).	Further	
studies	are	needed	to	reveal	the	mechanism	by	which	the	KLD	con‐
tributes	to	the	tumorigenic	function	of	GPNMB,	and	identification	
of	 the	 binding	 partner	 through	 this	 region	 is	 essential.	 The	Wnt/
PCP	 pathway	 must	 be	 the	 focus	 in	 studies	 of	 the	 phenotype	 of	
GPNMB(ΔKLD)	cell	tumors	in	the	future.
Glembatumumab	 vedotin,	 or	CDX‐011,	 an	Ab	 against	GPNMB	
conjugated	with	 an	 anticancer	 drug,	 has	 been	 developed	 to	 treat	
GPNMB‐expressing	cancers	and	is	in	clinical	trials	for	breast	cancer	
and	melanoma	patients.5,40‐43	This	suggests	the	potential	of	GPNMB	
as	a	therapeutic	target.	From	the	findings	of	this	study,	we	propose	
that	specifically	targeting	the	KLD	in	the	ECD	of	GPNMB	is	a	possi‐
ble	therapeutic	target.
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